LIVE

FLGT

Fulgent Genetics, Inc.

FLGT

NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $591.3M

$20.85

▲ +0.14%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$13.46 - $31.04

P/E

-8.76

Fwd P/E

-13.45

Beta

0.92

Div Yield

0.00%

Avg Vol

488.5K

Shares Out

31.2M

Mkt Cap

$591.3M

Price action

Price chart

Up 3.6% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Proprietary next-generation sequencing (NGS) platform enabling rapid, cost-effective testing at scale
  • Comprehensive test menu spanning oncology, carrier screening, infectious disease, and rare genetic disorders
  • Established relationships with major payors, hospitals, and medical institutions ensuring steady revenue streams
  • Vertical integration of laboratory operations reducing costs and improving turnaround times
  • Strategic partnerships with Helio Health and other entities expanding addressable market in early cancer detection
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Steady revenue growth (14% YoY)

Value

Deep value opportunity - significant discount to Life Sciences Tools peers

Momentum

Hot

+23.8% over 3m

Quality

Stable

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 30, 2026

“
Q2 26 RECAP

MAY 1, 2026

Reported EPS of -$0.36 vs -$0.35 consensus (-3.4% surprise). Revenue of $71.1M vs $68.1M expected (+4.5%).

EPS miss
Rev beat +4.5%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-3.4%

Next: Apr 30, 2026

Revenue trend · last 8Q

—

—

+8%

+14%

+15%

+17%

+9%

-3%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$71.0M

$71.7M

$76.2M

$73.5M

$81.8M

$84.1M

$83.3M

$71.1M

Margins · last 8Q

Gross

—

Operating

—

Profit

-34.9%

View full earnings history →

Wall Street consensus

1 analyst · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

1

100%

Sell

0%

Median Price Target

$15.00

▼ -28.1% vs $20.85

Low $15.00
Median $15.00
High $15.00

Latest: Piper Sandler · $15.00 · May 5, 2026

1 analyst covering

View full analyst page →

vs Industry

How FLGT stacks vs Medical - Diagnostics & Research

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.